1.
Feng Y, Wei H, Hsi J, Xing H, He X, Liao L, et al. Identification of a novel HIV type
1 circulating recombinant form (CRF65_cpx) composed of CRF01_AE and subtypes B and
C in western Yunnan, China. AIDS Res Hum Retroviruses. 2013;30(6):598-602.
2.
Liu Y, Gui T, Jia L, Li L, Bao Z, Li H, et al. Phylogenetic Analysis of HIV-1 CRF65_CPX
Reveals Yunnan Province Is Still a Source Contributing to the Spread of HIV-1 in China.
J Acquir Immune Defic Syndr. 2015;70(3):e120-e2.
3.
Lu X, Kang X, Liu Y, Cui Z, Guo W, Zhao C, et al. HIV-1 molecular epidemiology among
newly diagnosed HIV-1 individuals in Hebei, a low HIV prevalence province in China.
PLoS ONE. 2017;12(2):e0171481.
4.
Wang J-Y, Chen X-H, Shao B, Huo Q-Q, Liu S-Y, Li J, et al. Identification of a New
HIV-1 Circulating Recombinant Form CRF65_cpx Strain in Jilin, China. AIDS Res Hum
Retroviruses. 2018;34(8):709-13.
5.
Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, et al. A V106M mutation
in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside
reverse transcriptase inhibitors. AIDS. 2003;17(1):F1-F5.
6.
Kolomeets AN, Varghese V, Lemey P, Bobkova MR, Shafer RW. A uniquely prevalent nonnucleoside
reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.
AIDS. 2014;28(17):F1-F8.
7.
Tuaillon E, Gueudin M, Lemée V, Gueit I, Roques P, Corrigan GE, et al. Phenotypic
Susceptibility to Nonnucleoside Inhibitors of Virion-Associated Reverse Transcriptase
From Different HIV Types and Groups. J Acquir Immune Defic Syndr. 2004;37(5):1543-9.
8.
Zhou N, Nowicka-Sans B, McAuliffe B, Ray N, Eggers B, Fang H, et al. Genotypic correlates
of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the
prodrug BMS-663068. J Antimicrob Chemother. 2014;69(3):573-81.
9.
Shafer RW, Rhee S-Y, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease
and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21(2):215-23.
10.
Tambuyzer L, Azijn H, Lt, Vingerhoets J, Lecocq P, Kraus G, Picchio G, et al. Compilation
and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase
inhibitors. Antiviral Therapy. 2009;14(1):103-9.
11.
Melikian GL, Rhee S-Y, Varghese V, Porter D, White K, Taylor J, et al. Non-nucleoside
reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical
evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob
Chemother. 2014;69(1):12-20.
12.
Parkin NT, Gupta S, Chappey C, Petropoulos CJ. The K101P and K103R/V179D Mutations
in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to
Nonnucleoside Reverse Transcriptase Inhibitors. Antimicrob Agents Chemother. 2006;50(1):351-4.
13.
Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug Resistance
Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS
ONE. 2009;4(3):e4724.
14.
Li X, Xue Y, Lin Y, Gai J, Zhang L, Cheng H, et al. Evolutionary Dynamics and Complicated
Genetic Transmission Network Patterns of HIV-1 CRF01_AE among MSM in Shanghai, China.
Scientific Reports. 2016;6:34729.
15.
Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary
Genetics Analysis version 6.0. Mol Biol Evol. 2013;30(12):2725-9.
16.
Darriba D, Taboada GL, Doallo R, Posada D. jModelTest 2: more models, new heuristics
and parallel computing. Nat Meth. 2012;9(8):772-.
17.
Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms
and methods to estimate maximum-likelihood phylogenies: assessing the performance
of PhyML 3.0. Syst Biol. 2010;59(3):307-21.
18.
Feng Y, He X, Hsi JH, Li F, Li X, Wang Q, et al. The rapidly expanding CRF01_AE epidemic
in China is driven by multiple lineages of HIV-1 viruses introduced in the 1990s.
AIDS. 2013;27(11):1793-802.
19.
Pérez-Parra S, Álvarez M, Fernandez-Caballero JA, Pérez AB, Santos J, Bisbal O, et
al. Continued propagation of the CRF19_cpx variant among HIV-positive MSM patients
in Spain. J Antimicrob Chemother. 2018;73(4):1031-8.
20.
Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S. Combination of V106I and
V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase
Confers Resistance to Efavirenz and Nevirapine but Not Etravirine. Antimicrob Agents
Chemother. 2010;54(4):1596-602.
21.
Xu H-T, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, et al.
Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions
with the M184I mutation on defining patterns of resistance to nonnucleoside reverse
transcriptase inhibitors rilpivirine and etravirine. Antimicrob Agents Chemother.
2013;57(7):3100-9.
22.
Sluis-Cremer N, Jordan MR, Huber K, Wallis CL, Bertagnolio S, Mellors JW, et al. E138A
in HIV-1 reverse transcriptase is more common in subtype C than B: implications for
rilpivirine use in resource-limited settings. Antiviral Res. 2014;107:31-4.
23.
Giannini A, Vicenti I, Materazzi A, Boccuto A, Dragoni F, Zazzi M, et al. The HIV-1
reverse transcriptase E138A natural polymorphism decreases the genetic barrier to
resistance to etravirine in vitro. J Antimicrob Chemother. 2018;74(3):607-13.
24.
Chu Z-x, Xu J-j, Zhang Y-h, Zhang J, Hu Q-h, Yun K, et al. Poppers use and Sexual
Partner Concurrency Increase the HIV Incidence of MSM: a 24-month Prospective Cohort
Survey in Shenyang, China. Scientific Reports. 2018;8:24.
25.
Han X, An M, Zhang M, Zhao B, Wu H, Liang S, et al. Identification of 3 distinct HIV-1
founding strains responsible for expanding epidemic among men who have sex with men
in 9 Chinese cities. J Acquir Immune Defic Syndr. 2013;64(1):16-24.
26.
Han X, Takebe Y, Zhang W, An M, Zhao B, Hu Q, et al. A Large-scale Survey of CRF55_01B
from Men-Who-Have-Sex-with-Men in China: implying the Evolutionary History and Public
Health Impact. Scientific Reports. 2015;5:18147.